Human Leishmania Vaccine

Modality

Leishmaniasis is a deadly parasitic disease caused by Leishmania spp. and transmitted via sandfly bites. This illness is a globally public health emergency. Different Leishmania species can cause it to manifest in three distinct clinical forms: cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL). There isn't a registered vaccine against human leishmaniasis right now.

The following antigens have been the subject of intensive research on a number of recombinant subunit vaccine candidates: LeIF, gp63, p36/LACK, A-2, PSA-2/gp46/M-2, FML, LCR1, ORFF, KMP11, LmSTI1, TSA, HASPB1, protein Q, cysteine protease B (CPB), and A (CPA).

Development of Human Leishmania Vaccines

Phase II clinical studies for recombinant antigen vaccines based on LEISH-F1, LIESH-F2, and LEISH-F3 have been completed, indicating their potential as vaccine candidates against leishmaniasis. MPL-SE adjuvanted LEISH-F1 is made up of LEISH-F1 (Leish-111f), an engineered protein encoded by 3 genes: L. major homolog of eukaryotic thiol-specific antioxidant (TSA), stress-inducible protein-1 (LmSTI1), and L. braziliensis elongation and initiation factor (LeIF). LEISH-F2 is derived from LEISH-F1, with an amino acid replacement of glutamine (Gln) for Lys274, which enhances the production process.

GL-SE is an adjuvant present in LEISH-F3, but recombinant nucleoside hydrolase (NH) and sterol 24-c-methyltransferase (SMT) are present separately.

All Categories

Human Leishmania Vaccine

Modality

Human Leishmania Vaccine

Development of Human Leishmania Vaccines

Yaohai Bio-Pharma Offers One-Stop CDMO Solution for Leishmania Vaccines

MICROBIAL CDMO

Quick Links

GET IN TOUCH

Get in touch